Cyfuse Biomedical
The Regenova 3D bioprinter enables the creation of three-dimensional living tissue constructs using the innovative Kenzan method, which arranges cell spheroids onto needles for scaffold-free tissue construction.
- CEO / Founder
- Shizuka Akieda
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $35.3M
- Latest Round
- IPO - $18.5M - December 2022
- Key Investors
- University of Tokyo Edge Capital (UTEC); Nippon Venture Capital (NVCC); DBJ Capital; Industrial Growth Platform (IGPI); Shibuya Kogyo; M3; Daiwa; JAFCO; Mitsubishi UFJ Capital; SBI Securities Co., Ltd.; Okasan Securities Co., Ltd.
Technology & Products
Key Products
Cyfuse Biomedical's key products include the Regenova bio 3D printer, which utilizes the Kenzan method for scaffold-free tissue construction. They have also partnered with NSK to co-develop a new bio-3D printer with automated, cleanroom-ready production capabilities for regenerative medicine and 3D cell products. Additionally, they collaborate with PHC on 3D cell product production technology.
Technological Advantage
Capable of creating more complex and stable 3D tissue structures compared to traditional bioprinting methods.
Differentiation
Value Proposition
Enables the creation of functional 3D tissue constructs for regenerative medicine and drug discovery through an innovative, scaffold-free bioprinting method.
How They Differentiate
Differentiates itself through the unique Kenzan method which allows for scaffold-free tissue construction, offering more complex tissue architecture.
Market & Competition
Target Customers
Medical researchers, pharmaceutical companies, and healthcare institutions
Industry Verticals
["Regenerative Medicine","Pharmaceutical Research","Tissue Engineering"]
Competitors
Organovo; 3D Bioprinting Solutions; Aspect Biosystems
Growth & Milestones
Growth Metrics
Founded in 2010 in Tokyo, Japan, based on technology license from Kyushu University. Funding includes 540 million yen ($5.1 million) in 2013, 1.4 billion yen ($13 million) in 2015, and 1.5 billion yen ($14 million) in 2018, totaling over a decade from founding. As of 2015, had 22 employees, including 12 researchers and 3 engineers. Publicly listed on TSE Growth (Securities Code: 4892). Leadership changed from Koji Kuchiishi as President & CEO in 2015 to Shizuka Akieda as CEO as of March 2025. Has sold about 30 bioprinters to clients in Japan and the U.S. No recent revenue, employee counts post-2015, or customer sales numbers available.
Major Milestones
["First use of the Regenova 3D Bioprinter outside Japan through a partnership with Cell Applications, Inc."]
Notable Customers
Marubeni; Sysmex; PHC Corporation; Saga University Hospital